EC
DSGN icon

EcoR1 Capital’s Design Therapeutics DSGN Stock Holding History

EcoR1 Capital’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-426,683
Closed -$2.63M – 50
2024
Q4 		$2.63M Buy
426,683
+372,849
+693% +$2.16M 0.1% 49
2024
Q3 		$290K Buy
+53,834
New +$253K 0.01% 61
2023
Q1 		– Sell
-884,903
Closed -$9.08M – 61
2022
Q4 		$9.08M Sell
884,903
-1,634,365
-65% -$22.1M 0.28% 42
2022
Q3 		$42.1M Sell
2,519,268
-114,910
-4% -$2.29M 1.24% 18
2022
Q2 		$36.9M Buy
2,634,178
+262,733
+11% +$3.55M 1.27% 24
2022
Q1 		$38.3M Buy
2,371,445
+218,448
+10% +$3.35M 1.2% 23
2021
Q4 		$46.1M Buy
2,152,997
+289,899
+16% +$4.98M 1.47% 21
2021
Q3 		$27.4M Buy
1,863,098
+603,079
+48% +$10M 0.95% 19
2021
Q2 		$25.1M Buy
1,260,019
+122,079
+11% +$3.08M 0.94% 23
2021
Q1 		$34M Buy
+1,137,940
New +$38.4M 1.51% 19

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

EcoR1 Capital's DSGN Position: Q1 2025 in Review

EcoR1 Capital sold out of Design Therapeutics (DSGN) in Q1 2025, closing a stake of 426,683 shares — an estimated $2.63M sold.

EcoR1 Capital first reported a position in DSGN in Q1 2021 and held it in 10 quarters. The position peaked at $46.1M in Q4 2021. 98 funds tracked by Wall St. Rank hold DSGN as of Q1 2025.

  • EcoR1 Capital reported no remaining Design Therapeutics position as of Q1 2025 after selling out during the quarter.
  • EcoR1 Capital sold 426,683 Design Therapeutics shares in Q1 2025, an estimated $2.63M.
  • EcoR1 Capital first reported a position in Design Therapeutics in Q1 2021 and held it in 10 quarters.
  • EcoR1 Capital's Design Therapeutics position peaked at $46.1M in Q4 2021.
  • 98 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2025.

Based on EcoR1 Capital's 13F filing for Q1 2025, filed 15 May 2025.